(NASDAQ: MDCX) Medicus Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.98%.
Medicus Pharma's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast MDCX's revenue for 2028 to be $1,282,771,152, with the lowest MDCX revenue forecast at $1,282,771,152, and the highest MDCX revenue forecast at $1,282,771,152. On average, 1 Wall Street analysts forecast MDCX's revenue for 2029 to be $2,583,358,570, with the lowest MDCX revenue forecast at $2,583,358,570, and the highest MDCX revenue forecast at $2,583,358,570.
In 2030, MDCX is forecast to generate $5,148,900,874 in revenue, with the lowest revenue forecast at $5,148,900,874 and the highest revenue forecast at $5,148,900,874.